XL184

An orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. XL184 strongly binds to and… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2006-2018
0246820062018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
PURPOSE Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype that is associated with poor clinical outcome… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2014
2014
BACKGROUND Cabozantinib targets tyrosine kinases including MET, vascular endothelial growth factor (VEGF) receptor 2, and… (More)
Is this relevant?
2013
2013
Cabozantinib (XL184) is an oral multiple receptor tyrosine kinase inhibitor manufactured by Exelixis Inc., CA, USA. It mainly… (More)
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Is this relevant?
2013
2013
BACKGROUND A limited number of approved therapeutic options are available to metastatic medullary thyroid cancer (MTC) patients… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2012
Highly Cited
2012
UNLABELLED Invasion and metastasis increase after the inhibition of VEGF signaling in some preclinical tumor models. In the… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2012
2012
261 Background: Cabozantinib is an oral, potent inhibitor of MET and VEGFR2. MET over-expression has been observed in advanced… (More)
Is this relevant?
Highly Cited
2011
Highly Cited
2011
The signaling pathway of the receptor tyrosine kinase MET and its ligand hepatocyte growth factor (HGF) is important for cell… (More)
  • table 1
Is this relevant?
Highly Cited
2011
Highly Cited
2011
PURPOSE XL184 (cabozantinib) is a potent inhibitor of MET, vascular endothelial growth factor receptor 2 (VEGFR2), and RET, with… (More)
Is this relevant?
Highly Cited
2011
Highly Cited
2011
BACKGROUND & AIMS Growth of many different tumor types requires a population of self-renewing cancer stem cells (CSCs). c-Met is… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2011
Highly Cited
2011
Angiogenesis inhibitors that block VEGF receptor (VEGFR) signaling slow the growth of many types of tumors, but eventually the… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?